Vancouver, Canada – May 8, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces that Nucro-Technics Inc. (“Nucro-Technics”), a Toronto-based contract research organization collaborating with Onco on preclinical development, has commenced advanced bioanalytical work in support of the Company’s ongoing non-GLP[i] pharmacokinetic (PK) and biodistribution animal model study involving A83B4C63, the active pharmaceutical ingredient ("API") for Onco’s exclusively-licensed PNKP Inhibitor Technology (the ...
[ more ]
